{"id":"W2264465777","doi":"10.3111/13696998.2016.1151432","title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; McGill University; Golder Associates (Canada)","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Erlotinib; Nivolumab; Docetaxel; Quality-adjusted life year; Oncology; Lung cancer; Quality of life (healthcare); Cost effectiveness; Survival analysis; Internal medicine; Cancer; Immunotherapy; Epidermal growth factor receptor; Risk analysis (engineering)","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008419349,0.001634641,0.001246101,0.002129469,0.001412665,0.002440109,0.002028522,0.001255299,0.001978139],"category_scores_gemma":[0.02298786,0.0006125555,0.002057052,0.002564629,0.0008228954,0.0009090287,0.001359297,0.00127425,0.00009608243],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.08521019,"about_ca_system_score_gemma":0.04901507,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9158834,"about_ca_topic_score_gemma":0.8526226,"domain_scores_codex":[0.9962263,0.00240752,0.000154008,0.000182265,0.0006267389,0.0004032087],"domain_scores_gemma":[0.9895787,0.006691361,0.0007252249,0.0001892625,0.002264329,0.0005510311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.004999693,0.0007720597,0.02581959,0.001312526,0.001184682,0.0002110047,0.0002672743,0.9152192,0.0003495405,0.008841014,0.002170571,0.03885299],"study_design_scores_gemma":[0.0009874158,0.001123567,0.01857713,0.0003639433,0.0007701238,0.00007986882,0.0004820534,0.9733353,0.0003258705,0.001941436,0.00191995,0.00009332296],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9496212,0.009273515,0.01415724,0.003646811,0.0001197273,0.002139579,0.004195577,0.000150634,0.01669572],"genre_scores_gemma":[0.9898366,0.002118268,0.005638544,0.0001990478,0.00001479263,0.000364641,0.0009445027,0.00002229264,0.0008612328],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08521019,"threshold_uncertainty_score":0.6182461,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1385477431919973,"score_gpt":0.3627472802013817,"score_spread":0.2241995370093845,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}